SE9202128D0 - Precipitation of one or more active compounds in situ - Google Patents

Precipitation of one or more active compounds in situ

Info

Publication number
SE9202128D0
SE9202128D0 SE9202128A SE9202128A SE9202128D0 SE 9202128 D0 SE9202128 D0 SE 9202128D0 SE 9202128 A SE9202128 A SE 9202128A SE 9202128 A SE9202128 A SE 9202128A SE 9202128 D0 SE9202128 D0 SE 9202128D0
Authority
SE
Sweden
Prior art keywords
situ
active compounds
precipitation
solution
administration
Prior art date
Application number
SE9202128A
Other languages
English (en)
Swedish (sv)
Inventor
F Broberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9202128A priority Critical patent/SE9202128D0/xx
Publication of SE9202128D0 publication Critical patent/SE9202128D0/xx
Priority to IS4037A priority patent/IS4037A/is
Priority to JP50321794A priority patent/JP3809186B2/ja
Priority to PCT/SE1993/000566 priority patent/WO1994001087A1/fr
Priority to FI950074A priority patent/FI950074L/fi
Priority to DK93915076T priority patent/DK0648112T3/da
Priority to PT93915076T priority patent/PT648112E/pt
Priority to ES93915076T priority patent/ES2152255T3/es
Priority to AT93915076T priority patent/ATE196990T1/de
Priority to AU45194/93A priority patent/AU676177B2/en
Priority to DE69329576T priority patent/DE69329576T2/de
Priority to CA002139505A priority patent/CA2139505C/fr
Priority to EP93915076A priority patent/EP0648112B1/fr
Priority to NO950049A priority patent/NO950049L/no
Priority to US08/563,880 priority patent/US5916583A/en
Priority to GR20010400036T priority patent/GR3035220T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE9202128A 1992-07-09 1992-07-09 Precipitation of one or more active compounds in situ SE9202128D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE9202128A SE9202128D0 (sv) 1992-07-09 1992-07-09 Precipitation of one or more active compounds in situ
IS4037A IS4037A (is) 1992-07-09 1993-06-21 Staðbundin útfelling eins eða fleiri virkra efna
EP93915076A EP0648112B1 (fr) 1992-07-09 1993-06-24 Precipitation in situ d'un ou de plusieurs composes actifs
PT93915076T PT648112E (pt) 1992-07-09 1993-06-24 Precipitacao in situ de um ou mais compostos activos
AU45194/93A AU676177B2 (en) 1992-07-09 1993-06-24 Precipitation of one or more active compounds in situ
FI950074A FI950074L (fi) 1992-07-09 1993-06-24 Yhden tai useamman aktiivisen yhdisteen saostaminen in situ
DK93915076T DK0648112T3 (da) 1992-07-09 1993-06-24 Udfældning af en eller flere active forbindelser in situ
JP50321794A JP3809186B2 (ja) 1992-07-09 1993-06-24 現場での１種又はそれ以上の活性化合物の析出
ES93915076T ES2152255T3 (es) 1992-07-09 1993-06-24 Precipitacion in situ de uno o mas compuestos activos.
AT93915076T ATE196990T1 (de) 1992-07-09 1993-06-24 Präzipitation einer oder mehrerer aktiver verbindungen in situ
PCT/SE1993/000566 WO1994001087A1 (fr) 1992-07-09 1993-06-24 Precipitation in situ d'un ou de plusieurs composes actifs
DE69329576T DE69329576T2 (de) 1992-07-09 1993-06-24 Präzipitation einer oder mehrerer aktiver verbindungen in situ
CA002139505A CA2139505C (fr) 1992-07-09 1993-06-24 Precipitation d'au moins un compose actif in situ
NO950049A NO950049L (no) 1992-07-09 1995-01-05 Utfelling av en eller flere aktive forbindelser in situ
US08/563,880 US5916583A (en) 1992-07-09 1995-11-21 Precipitation of one or more active compounds in situ
GR20010400036T GR3035220T3 (en) 1992-07-09 2001-01-11 Precipitation of one or more active compounds in situ.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9202128A SE9202128D0 (sv) 1992-07-09 1992-07-09 Precipitation of one or more active compounds in situ

Publications (1)

Publication Number Publication Date
SE9202128D0 true SE9202128D0 (sv) 1992-07-09

Family

ID=20386754

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9202128A SE9202128D0 (sv) 1992-07-09 1992-07-09 Precipitation of one or more active compounds in situ

Country Status (16)

Country Link
US (1) US5916583A (fr)
EP (1) EP0648112B1 (fr)
JP (1) JP3809186B2 (fr)
AT (1) ATE196990T1 (fr)
AU (1) AU676177B2 (fr)
CA (1) CA2139505C (fr)
DE (1) DE69329576T2 (fr)
DK (1) DK0648112T3 (fr)
ES (1) ES2152255T3 (fr)
FI (1) FI950074L (fr)
GR (1) GR3035220T3 (fr)
IS (1) IS4037A (fr)
NO (1) NO950049L (fr)
PT (1) PT648112E (fr)
SE (1) SE9202128D0 (fr)
WO (1) WO1994001087A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138130T3 (es) 1995-10-28 2000-01-01 Braun Melsungen Ag Composicion farmaceutica que contiene un anestesico local y/o un analgesico de accion central.
FR2748207B1 (fr) 1996-05-06 1998-06-12 Cird Galderma Composition a base d'un compose modulant la reactivite des fibres nerveuses
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
JP4865183B2 (ja) * 2000-06-06 2012-02-01 レキオファーマ株式会社 病変異常組織治療用医薬組成物キット
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
NZ531460A (en) * 2001-10-19 2005-05-27 Idexx Lab Inc Controlled release - over at least 4-15 days - of injectable compositions comprising a lipophilic counterion such a saturated or unsaturated C10-C18 fatty acid
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
FR2862872A1 (fr) * 2003-12-02 2005-06-03 Palbian Snc Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol.
US7402320B2 (en) * 2004-08-31 2008-07-22 Vnus Medical Technologies, Inc. Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure
WO2006081238A2 (fr) 2005-01-25 2006-08-03 Vnus Medical Technologies, Inc. Structures pour l'occlusion permanente d'une structure anatomique creuse
US20060280786A1 (en) * 2005-06-14 2006-12-14 Rabinow Barrett E Pharmaceutical formulations for minimizing drug-drug interactions
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US8465451B2 (en) 2005-06-22 2013-06-18 Covidien Lp Methods and apparatus for introducing tumescent fluid to body tissue
CA2628630A1 (fr) * 2005-11-15 2007-05-24 Baxter International Inc. Compositions d'inhibiteurs de lipoxygenase
US9017361B2 (en) 2006-04-20 2015-04-28 Covidien Lp Occlusive implant and methods for hollow anatomical structure
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CA2914608A1 (fr) * 2013-03-14 2014-09-25 Jsn I, Llc Masquage du gout d'anesthesiques et d'analgesiques
LT3049055T (lt) * 2013-09-27 2018-07-25 Anteis S.A. Injekcinio hidrogelio, sterilizuoto karščiu, sudaryto iš hialurono rūgšties, turinčio miltelių pavidalo lidokaino ir šarminio agento, gamybos būdas
US20160367959A1 (en) * 2015-06-18 2016-12-22 Avon Products, Inc. Multiphase Compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268495A (en) * 1979-01-08 1981-05-19 Ethicon, Inc. Injectable embolization and occlusion solution
US4259331A (en) * 1979-04-16 1981-03-31 Pfizer Inc. Oxytetracycline compositions
US4599354A (en) * 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
US5051257A (en) * 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.

Also Published As

Publication number Publication date
US5916583A (en) 1999-06-29
NO950049D0 (no) 1995-01-05
JP3809186B2 (ja) 2006-08-16
FI950074A0 (fi) 1995-01-05
NO950049L (no) 1995-01-05
PT648112E (pt) 2001-01-31
FI950074A7 (fi) 1995-01-05
AU676177B2 (en) 1997-03-06
DE69329576D1 (de) 2000-11-23
AU4519493A (en) 1994-01-31
CA2139505C (fr) 2003-10-28
WO1994001087A1 (fr) 1994-01-20
GR3035220T3 (en) 2001-04-30
ATE196990T1 (de) 2000-11-15
IS4037A (is) 1994-01-10
EP0648112A1 (fr) 1995-04-19
DE69329576T2 (de) 2001-03-08
EP0648112B1 (fr) 2000-10-18
FI950074L (fi) 1995-01-05
DK0648112T3 (da) 2000-11-27
ES2152255T3 (es) 2001-02-01
CA2139505A1 (fr) 1994-01-20
JPH07509450A (ja) 1995-10-19

Similar Documents

Publication Publication Date Title
SE9202128D0 (sv) Precipitation of one or more active compounds in situ
EA200200645A1 (ru) Ингибиторы каспазы и их применение
WO1993000095A3 (fr) Antagonistes bicycliques de fibrinogene
BR0112068A (pt) Compostos orgânicos
YU164791A (sh) Nezasićene hidroksialkilhinolin kiseline
WO1992019211A3 (fr) Imidazobenzoquinones et composition contenant ces dernieres permettant de prevenir ou de traiter l'hypertension ou l'insuffisance cardiaque
FI944823A0 (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
DE69409796D1 (de) Neue verwendung bis-heterocyclische verbindungen und dessen zusammensetzungen
ATE147625T1 (de) Hydantoin- oder imidazolidintrionderivate zur vorbeugung oder behandlung von niereninsuffizienz
KR930012036A (ko) 골 흡수 억제용 약제학적 조성물
DK0922054T3 (da) Antikoagulerende peptidylargininaldehydderivater
ATE168679T1 (de) Neue tetracyclische verbindungen
ATE132039T1 (de) Verwendung von steroidderivaten zur behandlung der endometriose
DE3880564D1 (de) Arzneimittel zur behandlung von herzinsuffizienz.
DK0456792T3 (da) Forbedret transdermalt system til indgivelse af farmakologisk aktive forbindelser under pH-kontrollerede betingelser
EP0414903A4 (en) New thioproline derivative
EP0386258A4 (en) Tetrahydropyridine derivatives
ES2052962T3 (es) Microbicidas.
CS247287A2 (en) Method of injection applicable water solutions antimetic agent stabilization
TW360630B (en) A secoaporphine compounds on arrhythmia
TH23095A (th) อนุพันธ์พิรโรโลคาร์บาโซล ซึ่งใช้เป็นสารเคมีรักษาโรค
KR920021561A (ko) 신규의 세팔로스포린 및 그의 제조 방법